This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cyclacel Pharmaceuticals, Inc.
Drug Names(s): CYC116
Description: CYC116 inhibits Aurora kinase (AK) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Aurora kinases are enzymes that help dividing cells share their materials between two daughter cells. In many people with cancer, aurora kinase malfunctions and normal control of cell division is lost resulting in abnormal growth. Blocking VEGF receptors inhibits angiogenesis, the development of capillary blood vessels.
Pink Sheet Weekly Trademark Review June 4, 2013
Additional information available to subscribers only: